ArticleJMIR research protocols2017
Mobile Health Technology (mDiab) for the Prevention of Type 2 Diabetes: Protocol for a Randomized Controlled Trial.
Article in JMIR research protocols, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 14 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
14 citing papers in PubMed, 26 citations in OpenAlex.
- Precision Recruitment and Engagement of Individuals at Risk for Diabetes and Hypertension in Clinical Trials (PREDHICT): A Randomized Trial for an E-Persuasive Mobile Application to Inform Decision Making about Clinical Trials.International journal of environmental research and public health · 2023Trial
- Telemedicine-assisted structured self-monitoring of blood glucose in management of T2DM results of a randomized clinical trial.BMC medical informatics and decision making · 2023Trial
- Culturally Tailored Strategies to Enhance Type 2 Diabetes Care for South Asians in the United States.Journal of general internal medicine · 2024Article
- Designing and Evaluating a Personalized, Human-Centered Dietary Decision Support System for Use Among People With Diabetes in an Indian Setting: Protocol for a Quasi-Experimental Study.JMIR research protocols · 2022Article
- Digital health and diabetes: experience from India.Therapeutic advances in endocrinology and metabolism · 2021Review
- The clinical effects of a new management mode for hypertensive patients: a randomized controlled trial.Cardiovascular diagnosis and therapy · 2020Article
- Effectiveness of a Video-Based Lifestyle Education Program Compared to Usual Care in Improving HbA1c and Other Metabolic Parameters in Individuals with Type 2 Diabetes: An Open-Label Parallel Arm Randomized Control Trial (RCT).Diabetes therapy : research, treatment and education of diabetes and related disorders · 2020Article
- Application-based management of perioperative anticoagulant therapy: description of POPACTApp.Langenbeck's archives of surgery · 2019Article
- Impact of Use Frequency of a Mobile Diabetes Management App on Blood Glucose Control: Evaluation Study.JMIR mHealth and uHealth · 2019Article
- Behavioral Theory: The Missing Ingredient for Digital Health Tools to Change Behavior and Increase Adherence.Journal of diabetes science and technology · 2019Article
- Mobile health technology (WeChat) for the hierarchical management of community hypertension: protocol for a cluster randomized controlled trial.Patient preference and adherence · 2019Article
- The Impact of a Maternal Education Program Through Text Messaging in Rural China: Cluster Randomized Controlled Trial.JMIR mHealth and uHealth · 2018Article
- Nutrition and diabetes in South Asia.European journal of clinical nutrition · 2018Review
- Change in cardiometabolic risk factors among Asian Indian adults recruited in a mHealth-based diabetes prevention trial.Digital healthArticle
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors at 3 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundThe prevalence of type 2 diabetes is increasing in epidemic proportions in low- and middle-income countries. There is an urgent need for novel methods to tackle the increasing incidence of diabetes. The ubiquity of mobile phone use and access to Internet makes mobile health (mHealth) technology a viable tool to prevent and manage diabetes.
objectiveThe objective of this randomized controlled trial is to implement and evaluate the feasibility, cost-effectiveness, and sustainability of a reality television-based lifestyle intervention program. This intervention program is delivered via a mobile phone app (mDiab) to approximately 1500 Android smartphone users who are adults at a high risk for type 2 diabetes from three cities in India, namely, Chennai, Bengaluru, and New Delhi.
methodsThe mDiab intervention would be delivered via a mobile phone app along with weekly coach calls for 12 weeks. Each participant will go through a maintenance phase of 6 to 8 months post intervention. Overall, there would be 3 testing time points in the study: baseline, post intervention, and the end of follow-up. The app will enable individuals to track their weight, physical activity, and diet alongside weekly video lessons on type 2 diabetes prevention.
resultsThe study outcomes are weight loss (primary measure of effectiveness); improvement in cardiometabolic risk factors (ie, waist circumference, blood pressure, glucose, insulin, and lipids); and improvement in physical activity, quality of life, and dietary habits. Sustainability will be assessed through focus group discussions.
conclusionsIf successful, mDiab can be used as a model for translational and implementation research in the use of mHealth technology for diabetes prevention and may be further expanded for the prevention of other noncommunicable diseases such as hypertension and cardiovascular diseases.
trial registrationClinical Trials Registry of India CTRI/2015/07/006011 http://ctri.nic.in/Clinicaltrials/pdf_generate.php? trialid=11841 (Archived by WebCite at http://www.webcitation.org/6urCS5kMB).
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.